The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

Biotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make ...

They could perhaps see sustained runs beyond this year.

TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target.

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Biotech stocks are in focus as analysts track upcoming clinical data and regulatory decisions in autoimmune and rare disease ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.